Analystreport

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at HC Wainwright from $55.00 to $60.00. They now have a "neutral" rating on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com